Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 6:42 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1345–1368 of 7,390 matching trials from the live ClinicalTrials.gov search.
Conditions
Carcinoma, Renal Cell
Interventions
Topotecan, Radiation therapy
Drug · Radiation
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Locally Advanced Solid Tumors, Metastatic Solid Tumors
Interventions
retifanlimab
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
8
States / cities
Scottsdale, Arizona • Grand Rapids, Michigan • New Brunswick, New Jersey + 4 more
Conditions
Healthy Volunteers
Interventions
Danicamtiv, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Anaheim, California
Conditions
Non-small Cell Lung Cancer
Interventions
ALT-803, Nivolumab
Biological
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
4
States / cities
Weston, Florida • Minneapolis, Minnesota • Cleveland, Ohio + 1 more
Active, not recruiting Phase 1 Interventional

huCART19-IL18 in CD19+ Cancers

NCT04684563
Conditions
Chronic Lymphocytic Leukemia, Non-hodgkin Lymphoma, Acute Lymphoblastic Leukemia
Interventions
huCART19-IL18
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2036
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Acneiform Eruption Due to Chemical, Xerosis Cutis, Paronychia
Interventions
HT-001 2% Topical Gel, HT-001 1% Topical Gel, HT-001 0.5% Topical Gel, HT-001 Placebo
Drug
Lead sponsor
Hoth Therapeutics, Inc.
Other
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
9
States / cities
Irvine, California • Orange, California • Miami, Florida + 6 more
Conditions
Prostate Cancer
Interventions
[18F]FluorThanatrace, Poly(ADP Ribose) Polymerase 1
Device · Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Advanced Cancer, Solid Tumor
Interventions
MRTX1719, Olaparib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Houston, Texas
Conditions
Brain Tumor Adult
Interventions
MR Perfusion Scan, 2HG Spectroscopy Scan, Standard of Care Intraoperative MRI
Device
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Diabetes Mellitus, Type 1 Diabetes, Cardiovascular Diseases (CVD), Severe Albuminuria, Estimated Glomerular Filtration Rate (eGFR), Hypoglycemia (Diabetic), Vascular Calcification, Carotid-femoral Pulse Wave Velocity, Kidney Diseases
Interventions
Routine/prescribed exogenous insulin dose
Drug
Lead sponsor
Rachel Miller
Other
Eligibility
Not listed
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Lymphocytic Leukemia, Chronic
Interventions
Obinutuzumab, Venetoclax
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
7
States / cities
La Jolla, California • Denver, Colorado • New York, New York + 4 more
Conditions
Myeloid Malignancy, Hematologic Malignancy, Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions
G-CSF, Decitabine, Venetoclax
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Drug Interactions
Interventions
Prednisone, VX-509, Methylprednisolone
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Lenexa, Kansas
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Gemcitabine, ACR-368
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Tampa, Florida
Completed Early Phase 1 Interventional Accepts healthy volunteers

Can Biotin Supplementation be Used to Mask hCG Abuse?

NCT05450900
Conditions
Healthy
Interventions
Choriogonadotropin Alpha, biotin, Microcellulose filler
Drug · Dietary Supplement · Other
Lead sponsor
Sports Medicine Research and Testing Laboratory
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Completed Phase 2 Interventional Results available

Safety and Efficacy of AIN457 in Noninfectious Uveitis

NCT00685399
Conditions
Non-infectious Uveitis
Interventions
AIN457, AIN 457
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
20
States / cities
Beverly Hills, California • Los Angeles, California • Sacramento, California + 16 more
Completed No phase listed Observational Accepts healthy volunteers

Assessing Speech Perception and Amplification Benefit During Infancy

NCT05653999
Conditions
Hearing Loss, Children With Hearing Differences, Amplification, Speech Perception
Interventions
Hearing Aids
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
6 Months to 36 Months
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Ewing Sarcoma, Round Cell Sarcoma With EWSR1-non-ETS Fusion
Interventions
Biospecimen Collection, Chemotherapy, Computed Tomography, Conventional Radiotherapy, Definitive Surgical Resection, Dose-escalated Radiation Therapy, Electronic Health Record Review, External Beam Radiation Therapy, Hypofractionated Radiation Therapy, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, Radiation Therapy
Procedure · Drug · Radiation + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
2 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
2
States / cities
Phoenix, Arizona • Rochester, Minnesota
Conditions
POTS - Postural Orthostatic Tachycardia Syndrome
Interventions
Questionnaires to be competed, Provide list of medication and lifetime events, Use phone App to record new life events, Will wear an activity monitor, Periodic 24-hour urine sodium check, A fMRI scan, A bedside tilt test will be performed, IV placed to collect blood samples, Stool Sample
Behavioral · Device · Other + 1 more
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
12 Years to 21 Years · Female only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
HER2-positive Breast Cancer, HER-2 Protein Overexpression, HER-2 Gene Amplification, HER2 Gene Mutation
Interventions
ORM-5029
Drug
Lead sponsor
Orum Therapeutics USA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • Boston, Massachusetts + 7 more
Conditions
Pleural Malignant Mesothelioma
Interventions
Laboratory Biomarker Analysis, Palliative Radiation Therapy, Pembrolizumab, Radiation Therapy
Other · Radiation · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Houston, Texas
Conditions
Advanced Prostate Cancer, Metastatic Prostate Cancer
Interventions
RO7656594
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
5
States / cities
Scottsdale, Arizona • New Haven, Connecticut • Orlando, Florida + 2 more
Conditions
Multiple Myeloma
Interventions
CC-92480, Bortezomib, Dexamethasone, Daratumumab, Carfilzomib, Elotuzumab, Isatuximab
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
424 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
16
States / cities
Denver, Colorado • Tampa, Florida • Atlanta, Georgia + 10 more
Conditions
Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Pediatric SLE, Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Pediatric-Onset Multiple Sclerosis (POMS)
Interventions
Moderna mRNA-1273, BNT162b2, Ad26.COV2.S, Continue IS (MMF or MPA), Continue IS (MTX), Continue IS (B cell depletion therapy), Monovalent [B.1.351] CoV2 preS dTM-AS03, Withhold IS (MMF or MPA), Withhold IS (MTX), Withhold IS (B cell depletion therapy), Moderna mRNA-1273, Bivalent, BNT162b2, Bivalent
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
29
States / cities
Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 18 more